SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff, alongside declines in other crypto assets and stocks, is dominating discussion, with traders pointing to leveraged long liquidations and thin weekend liquidity as possible drivers. The community is split between buying the dip and warning that forced selling could deepen the decline.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention amid a sharp crypto-wide selloff, with traders linking its decline to Bitcoin weakness and concerns about continued liquidations. The community is split between calling it capitulation and buying the dip, while others expect further losses and question the tokens value.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

A broad crypto selloff has dragged Ethereum sharply lower, with traders pointing to forced liquidations, ETF outflows, and risk-off sentiment amid rate fears and weakness in tech stocks. The community is split between calling the decline a capitulation and buying the dip, and warning that selling pressure could continue.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp selloff is weighing on Strategy, which traders view as a leveraged proxy for BTC; discussion is compounded by MSCIs planned index removal and concerns about passive selling and pressure on the companys financing strategy. The reaction is broadly bearish, with some traders expecting further losses while others see a buying opportunity or potential rebound.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,493,507.45679271 with 591,519,914.8768357 in circulation. The last known price of Solana is 77.75210106 USD and is down -4.52 over the last 24 hours. It is currently trading on 1189 active market(s) with $3,771,510,230.13 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is plunging amid a broad crypto-market selloff and Bitcoin weakness, with traders pointing to heavy selling and liquidations as pressure builds. The community is split between buying and staking the dip and warning that the decline may deepen, with some questioning whether a durable bottom has formed.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a steep slide alongside the broader crypto market, with traders focused on further downside and whether the selloff has reached a floor. The conversation is split between holders calling it a buying opportunity and bearish traders warning that losses could deepen.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention as Ethereum and crypto weakness weigh on the companys ETH-treasury-linked shares. Traders are divided between viewing the discount to underlying assets and potential buybacks as an opportunity and worrying that continued ETH weakness, dilution, and managements capital-allocation decisions could prolong the slump.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 471,413,006.3506458 with 446,411,006.3506458 in circulation. The last known price of Avalanche is 8.22945358 USD and is down -1.18 over the last 24 hours. It is currently trading on 1135 active market(s) with $300,004,829.78 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

AVAX is selling off amid broad Bitcoin-led weakness in altcoins, with traders pointing to its steep losses and difficulty holding earlier gains. The community is also debating why the price faded despite excitement around the NYSEs Avalanche tokenized-securities plans, while some view the decline as a buying opportunity.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 159.21664083 USD and is down -1.76 over the last 24 hours. It is currently trading on 414 active market(s) with $110,625,382.40 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

Quant is drawing attention amid a steep pullback and volatile trading, which many traders link to weakness across crypto and Bitcoin after a prior rally; some fear further declines, while others are buying the dip and debating support levels. Longer-term bullish posts cite Quants anticipated role in tokenized banking and a Clearing House network planned for 2027, though that adoption remains a future catalyst.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is under pressure after a steep pullback amid broader crypto weakness and liquidation concerns. Traders are divided between calling the drop an oversold buying opportunity and warning that support has failed and further losses may follow.

statis crypto Watchlist

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medical ETF (MEDX) Touches New 52-Week High

MEDX hits a new 52-week high, as strength in patented pharma fuels fresh momentum.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

Equity

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 


Listed Funds Trust - Horizon Kinetics Medical ETF

Neutral Sentiment

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

American Century ETF Trust - Avantis International Large Cap Value ETF

EA Series Trust - Altrius Global Dividend ETF

Medarex, Inc.

Novartis AG

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

MEDX News